Science of NAD+

Function of NAD+

NAD+ (Nicotinamide Adenine Dinucleotide) is an essential cofactor for enzymes that control the metabolic activity in your cells. Changes in NAD+ levels lead to changes in the functioning of mitochondria, which are the cell’s energy producing organs. Age associated decreases in NAD+ levels cause diminished mitochondrial energy production, leading to metabolic disorders like type-2 diabetes, and non-alcoholic fatty liver disease. NAD+ is also an essential cofactor for enzymes that control DNA repair (enzymes called PARPs), and cellular metabolism (enzymes call Sirtuins).

 

Low NAD+ in Disease States

Impaired NAD+ mediated Sirtuin signaling in the cell is implicated in the development of insulin resistance and type-2 diabetes [1-7], as well as non-alcoholic fatty liver disease (NAFLD). NAFLD is the most common liver disease in the Western World, leading to inflammation that can progress to cirrhosis or liver cancer. Zhou et al. [8] showed that liver NAD+ levels decline with aging in humans. Evidence suggests that decreased NAD+ dependent Sirtuin action contributes to the formation of NAFLD [9-13]. Human studies are currently being designed to investigate replenishing liver NAD+ levels, thus activating Sirtuins to reverse metabolic dysfunction at the root of NAFLD.

 

Role of NAD+ in Aging

As we age, NAD+ levels progressively decrease which contributes to the general decline associated with aging [14-15]. Inflammation and oxidation further reduce levels of NAD+ which, in turn, reduces Sirtuin activity. Together, NAD+ and Sirtuins regulate numerous pathways that control our aging and lifespan[17-19]. Mammals contain seven Sirtuin enzymes (SIRT1–7) that have a wide variety of biological functions including control of cellular metabolism and energy, aging and longevity, cell survival, DNA repair, and stress resistance. Boosting cellular NAD+ levels serves as a powerful means to activate Sirtuins, and as a potential therapy for age-related disorders and the general decline associated with aging.

 

References

  1. Wang R, Kim H, Xiao C, Xu X. Hepatic Sirt1 deficiency in mice impairs mTorc2 / Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. J Clin Invest. 2011;121(11):4477–4490.
  2. Liang F, Chen R, Nakagawa A, Nishizawa M, Tsuda S, Wang H, Koya D. Low-frequency electroacupuncture improves insulin sensitivity in obese diabetic mice through activation of SIRT1/PGC-1a in skeletal muscle. Evidence-based Complement Altern Med. 2011;2011:735297. 10.1155/2011/735297.
  3. Zhang H-H, Ma X-J, Wu L-N, Zhao YY, Zhang PY, Zhang YH, Shao MW, Liu F, Li F, Qin GJ. SIRT1 attenuates high glucose-induced insulin resistance via reducing mitochondrial dysfunction in skeletal muscle cells. Exp Biol Med (Maywood). 2015;240(5):557–565.
  4. Frojdo S, Durand C, Molin L, Carey AL, El-Osta A, Kingwell BA, Febbraio MA, Solari F, Vidal H, Pirola L. Phosphoinositide 3-kinase as a novel functional target for the regulation of the insulin signaling pathway by SIRT1. Mol Cell Endocrinol. 2011;335(2):166–176.
  5. Chalkiadaki A, Guarente L. High-fat diet triggers inflammation-induced cleavage of SIRT1 in adipose tissue to promote metabolic dysfunction. Cell Metab. 2012;16(2):180–188.
  6. Rutanen J, Yaluri N, Modi S, Pihlajam¨ aki J, V¨ anttinen M, Itkonen P, Kainulainen S, Yamamoto H,Lagouge M, Sinclair DA, Elliott P, Westphal C, Auwerx J, Laakso M. SIRT1 mRNA expression may be associated with energy expenditure and insulin sensitivity. Diabetes. 2010;59(4):829–835.
  7. Xu C, Bai B, Fan P, Cai Y, Huang B, Law IK, Liu L, Xu A, Tung C, Li X, Siu FM, Che CM, Vanhoutte PM, Wang Y. Selective overexpression of human SIRT1 in adipose tissue enhances energy homeostasis and prevents the deterioration of insulin sensitivity with ageing in mice. Am J Transl Res. 2013;5(4):412–426
  8. Zhou C-C, Yang X, Hua X, Liu J, Fan MB, Li GQ, Song J, Xu TY, Li ZY, Guan YF, Wang P, Miao CY.Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing. Br J Pharmacol. 2016;173(15):2352–2368
  9. Kendrick AA, Choudhury M, Rahman SM, McCurdy CE, Friederich M, Van Hove JL, Watson PA, Birdsey N, Bao J, Gius D, Sack MN, Jing E, Kahn CR, Friedman JE, Jonscher KR. Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation. Biochem J. 2011;433(3):505–514
  10. Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB, Grueter CA, Harris C, Biddinger S, Ilkayeva OR, Stevens RD, Li Y, Saha AK, Ruderman NB, Bain JR, Newgard CB, Farese RV, Jr, Alt FW, Kahn CR, Verdin E. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature. 2010;464(7285):121–125.
  11. Min HK, Kapoor A, Fuchs M, Mirshahi F, Zhou H, Maher J, Kellum J, Warnick R, Contos MJ, Sanyal AJ. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 2012;15(5):665–674.
  12. Xu F, Gao Z, Zhang J, Rivera CA, Yin J, Weng J, Ye J. Lack of SIRT1 (Mammalian Sirtuin 1) activity leads to liver steatosis in the SIRT1+/- mice: a role of lipid mobilization and inflammation. Endocrinology. 2010;151(6):2504–2514.
  13. Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009;9(4): 327–338
  14. Chini CCS, Tarrag´ o MG, Chini EN. NAD and the aging process: Role in life, death and everything in between [published online ahead of print November 5, 2016]. Mol Cell Endocrinol.
  15. Imai S. Dissecting systemic control of metabolism and aging in the NAD world: the importance of SIRT1 and NAMPT-mediated NAD biosynthesis. FEBS Lett. 2011;585(11):1657–1662
  16. Yoshino, J., Mills, K. F., Yoon, M. J. & Imai, S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 14, 528–536 (2011)
  17. Satoh A, Brace CS, Rensing N, Cliften P, Wozniak DF, Herzog ED, Yamada KA, Imai S. Sirt1 extends life span and delays aging in mice through the regulation of Nk2 homeobox 1 in the DMH and LH. Cell Metab. 2013;18(3):416–430.
  18. Kanfi Y, Naiman S, Amir G, Peshti V, Zinman G, Nahum L, Bar-Joseph Z, Cohen HY. The Sirtuin SIRT6 regulates lifespan in male mice. Nature. 2012;483(7388):218–221.
  19. Schmeisser K, Mansfeld J, Kuhlow D, Weimer S, Priebe S, Heiland I, Birringer M, Groth M, Segref A, Kanfi Y, Price NL, Schmeisser S, Schuster S, Pfeiffer AF, Guthke R, Platzer M, Hoppe T, Cohen HY, Zarse K, Sinclair DA, Ristow M. Role of sirtuins in lifespan regulation is linked to methylation of nicotinamide. Nat Chem Biol. 2013;9(11):693–700